Cargando…

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer

[Image: see text] Introduction: Immune checkpoint inhibitors (ICIs) have provided noteworthy benefits in multiple cancer patients. However, the efficacy of monotherapy of ICIs was very limited. In this study, we endeavored to explore whether losartan can modulate the solid tumor microenvironment (TM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiuying, Luo, Xianqin, Hu, Shunqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tabriz University of Medical Sciences (TUOMS Publishing Group) 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182444/ https://www.ncbi.nlm.nih.gov/pubmed/37193073 http://dx.doi.org/10.34172/bi.2023.24166

Ejemplares similares

Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers
por: Ba, Hongping, et al.
Publicado: (2023)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
por: Qu, Qiuxia, et al.
Publicado: (2020)

Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma
por: Chen, Yezi, et al.
Publicado: (2022)

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis
por: Wei, Joe Q., et al.
Publicado: (2023)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
por: Passariello, Margherita, et al.
Publicado: (2019)

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
por: Bolaños-Mateo, Elixabet, et al.
Publicado: (2014)

Near‐infrared fluorescence‐labeled anti‐PD‐L1‐mAb for tumor imaging in human colorectal cancer xenografted mice
por: Zhang, Mingyu, et al.
Publicado: (2019)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review
por: Shang, Jingyuan, et al.
Publicado: (2022)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
por: Golay, Josée, et al.
Publicado: (2020)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

Plant Recycling for Molecular Biofarming to Produce Recombinant Anti-Cancer mAb
por: Kim, Deuk-Su, et al.
Publicado: (2016)

Expression and in vitro function of anti-cancer mAbs in transgenic Arabidopsis thaliana
por: Song, Ilchan, et al.
Publicado: (2020)

Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
por: Wang, Dengli, et al.
Publicado: (2022)

Norepinephrine inhibits CD8(+) T-cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma
por: Geng, Qishun, et al.
Publicado: (2023)

Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment
por: Kansy, Benjamin A, et al.
Publicado: (2015)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using (2) (1) (2)Pb
por: Boudousq, Vincent, et al.
Publicado: (2013)

Endoplasmic reticulum retention motif fused to recombinant anti-cancer monoclonal antibody (mAb) CO17-1A affects mAb expression and plant stress response
por: Song, Ilchan, et al.
Publicado: (2018)

A combination of anti‐PD‐L1 mAb plus Lm‐LLO‐E6 vaccine efficiently suppresses tumor growth and metastasis in HPV‐infected cancers
por: Lin, Po‐Lin, et al.
Publicado: (2017)

Anti-NKG2D mAb: A New Treatment for Crohn’s Disease?
por: Vadstrup, Kasper, et al.
Publicado: (2017)

A humanized anti‐cocaine mAb antagonizes the cardiovascular effects of cocaine in rats
por: Koch, Sheryl E., et al.
Publicado: (2023)

LPS combined with CD47mAb enhances the anti‑osteosarcoma ability of macrophages
por: Yuan, Peng, et al.
Publicado: (2023)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9(+) tumors
por: Santamaria, Silvia, et al.
Publicado: (2022)

Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor
por: Liu, Jingxian, et al.
Publicado: (2019)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
por: Alig, Annabel H. S., et al.
Publicado: (2022)

Novel strategy for a high-yielding mAb-producing CHO strain (overexpression of non-coding RNA enhanced proliferation and improved mAb yield)
por: Tabuchi, Hisahiro
Publicado: (2013)

Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
por: Morales-Kastresana, Aizea, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ktenufen3u8crb9ha4qj1800la